Archemix and Lilly in Aptamer deal
This article was originally published in Scrip
Archemix and Lilly are to explore the development of new aptamer-based drugs. The US biotechnology company will license certain IP rights from Lilly, which in return has an option to evaluate aptamers for certain drug targets. Lilly retains an option to enter into an exclusive licence with Archemix for up to two of the aptamer targets. No financial details were disclosed. Aptamers are synthetically derived oligonucleotides (short nucleic acid sequences) that bind to protein targets with high affinity and specificity and can be designed to have a specified duration of action.
You may also be interested in...
Laura Gonz�lez-Molero will be celebrating her first anniversary as President of Bayer HealthCare Pharmaceuticals, Latin America this month. With Bayer posting total sales of €1.05bnin Latin America in 2014, up 13% over 2013, Ms Gonz�lez-Molero should be pleased with a successful inaugural year. Resolute in her belief that innovation, "part of Bayer's DNA," will determine the company's long-term success in Latin America, rather than growth through acquisition, Ms Gonz�lez-Molero talks to Scrip about her personal ambitions for the company and the region.
A decade since its formation Anvisa, Brazil's medicines regulator, has shaken up the country's framework for ensuring drug quality. Yet the agency's approaches to drug pricing and registration have left some multinationals wanting, reports Sita Shah.
Elan is raising $1.5 billion in bonds to refinance its existing debt and for general corporate purposes, it says.